Asciminib as a new option in the treatment of chronic myeloid leukemia

被引：9
作者：
Ibis, Betul [1 ]
Tiribelli, Mario [2 ]
Eskazan, Ahmet Emre [3 ]
机构：
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Istanbul, Turkey
[2] Univ Udine, Dept Med Area, Div Hematol & Blood & Marrow Transplantat, Udine, Italy
[3] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Div Hematol, Dept Internal Med, Istanbul, Turkey
来源：
FUTURE ONCOLOGY | 2021年 / 17卷 / 36期
关键词：
ABL myristoyl pocket; asciminib; chronic myeloid leukemia; T315I; tyrosine kinase inhibitor; PONATINIB; EFFICACY;
D O I：
10.2217/fon-2021-1174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：5003 / 5005
页数：3
相关论文
共 21 条
[1]  
[Anonymous], 2021, FRONTLINE ASCIMINIB
[2]  
[Anonymous], 2021, PABL001 DASATINIB PR
[3]  
[Anonymous], 2021, ABL001 TREATMENT CHR
[4]  
[Anonymous], 2021, ASCIMINIB MONOTHERAP
[5]  
[Anonymous], 2021, A Study of the Efficacy and Safety of Guselkumab and Golimumab in Participants with Active Psoriatic Arthritis
[6]   Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia [J].
Chan, Onyee ;
Talati, Chetasi ;
Isenalumhe, Leidy ;
Shams, Samantha ;
Nodzon, Lisa ;
Fradley, Michael ;
Sweet, Kendra ;
Pinilla-Ibarz, Javier .
BLOOD ADVANCES, 2020, 4 (03) :530-538
[7]  
Cortes J, 2019, EHA, V3, P398
[8]  
Cortes J., 2019, HemaSphere, V3, P397
[9]   Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial [J].
Cortes, Jorge E. ;
Hughes, Timothy P. ;
Mauro, Michael J. ;
Hochhaus, Andreas ;
Rea, Delphine ;
Goh, Yeow Tee ;
Janssen, Jeroen ;
Steegmann, Juan Luis ;
Heinrich, Michael C. ;
Talpaz, Moshe ;
Etienne, Gabriel ;
Breccia, Massimo ;
Deininger, Michael W. ;
le Coutre, Philipp D. ;
Lang, Fabian ;
Aimone, Paola ;
Polydoros, Fotis ;
Cacciatore, Silvia ;
Stenson, Laura ;
Kim, Dong-Wook .
BLOOD, 2020, 136
[10]   Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants [J].
Eide, Christopher A. ;
Zabriskie, Matthew S. ;
Stevens, Samantha L. Savage ;
Antelope, Orlando ;
Vellore, Nadeem A. ;
Than, Hein ;
Schultz, Anna Reister ;
Clair, Phillip ;
Bowler, Amber D. ;
Pomicter, Anthony D. ;
Yan, Dongqing ;
Senina, Anna, V ;
Qiang, Wang ;
Kelley, Todd W. ;
Szankasi, Philippe ;
Heinrich, Michael C. ;
Tyner, Jeffrey W. ;
Rea, Delphine ;
Cayuela, Jean-Michel ;
Kim, Dong-Wook ;
Tognon, Cristina E. ;
O'Hare, Thomas ;
Druker, Brian J. ;
Deininger, Michael W. .
CANCER CELL, 2019, 36 (04) :431-+
123